The Colombian government remains in the crosshairs of the pharmaceutical industry.
In comments filed with the US trade representative, the Pharmaceutical Research & Manufacturers of America argued that Colombia should be given added scrutiny for purportedly failing to sufficiently protect and enforce patent rights. The remarks from the trade group were submitted as the US Trade Rep prepares its priority watch list of countries that are singled out for practices deemed both favorable and unfavorable to American companies.
Each year, PhRMA submits a list of countries that it believes poses a threat to global drug makers. Colombia has previously appeared on the priority watch list, but in its comments, which were filed on Wednesday, the industry group this year made a point of highlighting Colombia in a passage in which the trade rep is urged to “prioritize action.”